In addition, it was reported that GEFR promoted the activation of newly synthesised KRAS, and aurora kinase A (AURKA) avoided drug-induced tumour cells by interacting with KRAS (G12C) and the downstream protein c-RAF177. This evidence concerns the gene KRAS and neoplasm.